Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients

Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01040936

Acronym

ILLEPE-ACS

Enrollment

300

Registered

2009-12-30

Start date

2010-05-31

Completion date

2011-11-30

Last updated

2011-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

acute coronary syndrome, intervention, outcome, patients diagnosed ad Non-ST elevation ACS, patients received PCI therapy

Brief summary

PCI has been one of the most common choice of treatments for patients with coronary artery disease, and studies indicated that intensive statin treatment before PCI could reduce adverse events as comparing to the placebo. In China, statin with regular dose is currently applied to the patients admitted for Non-ST-elevation acute coronary syndrome (ACS). Here we hypothesize that intensive statin treatment with arovastatin before PCI could further reduce clinical adverse events.

Interventions

DRUGAtorvastatin

patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* finish informed consent * age≥18y and under 75y * diagnosed as non-ST elevation acute coronary syndrome, including unstable angina and non-ST elevation myocardial infarction * willing to receive the coronary angiography and potential PCI therapy

Exclusion criteria

* patient was treated by statins before randomization * stable angina or ST elevation myocardial infarction * without informed consent * abnormal liver function before randomization, (AST，ALT≥3ULN) * active hepatitis or muscular disease * impaired renal function with serum creatinine level \> 3mg/dl * impaired left ventricular systolic function with LVEF\< 30% * participating in other studies * non-PCI treated patients after coronary angiography will be washed out

Design outcomes

Primary

Measure	Time frame
The primary end point was the composite of major adverse cardiac events (MACE), including cardiac death, non-fatal reinfarction, and target vessel revascularization (TVR) at one-year clinical follow-up after randomization.	one year

Secondary

Measure	Time frame
rate of peri-procedural myocardial infarction	30days
MACE at 30d after randomization 3. changes of left ventricular function at 30d after randomization	30 days
changes of left ventricular function at 30d after randomization	30 days

Countries

China

Contacts

Primary ContactQi Zhang, MD

zhangqnh@yahoo.com+862164370045

Backup ContactXin Chen, MD

rjchenxin@yahoo.com.cn+862164370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026